EBS
Price
$1.97
Change
-$0.20 (-9.22%)
Updated
Apr 25, 6:59 PM EST
6 days until earnings call
GOSS
Price
$0.67
Change
-$0.04 (-5.63%)
Updated
Apr 25, 6:59 PM EST
19 days until earnings call
Ad is loading...

EBS vs GOSS ᐉ Comparison: Which is Better to Invest?

Header iconEBS vs GOSS Comparison
Open Charts EBS vs GOSSBanner chart's image
Emergent Biosolutions
Price$1.97
Change-$0.20 (-9.22%)
Volume$441.19K
CapitalizationN/A
Gossamer Bio
Price$0.67
Change-$0.04 (-5.63%)
Volume$1.99M
CapitalizationN/A
View a ticker or compare two or three
EBS vs GOSS Comparison Chart

Loading...

EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GOSSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
EBS vs. GOSS commentary
Apr 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and GOSS is a Hold.

COMPARISON
Comparison
Apr 25, 2024
Stock price -- (EBS: $2.18 vs. GOSS: $0.71)
Brand notoriety: EBS and GOSS are both not notable
EBS represents the Pharmaceuticals: Other, while GOSS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: EBS: 22% vs. GOSS: 53%
Market capitalization -- EBS: $120.07M vs. GOSS: $159.78M
EBS [@Pharmaceuticals: Other] is valued at $120.07M. GOSS’s [@Biotechnology] market capitalization is $159.78M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $567.76B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.82B. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, EBS is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 4 TA indicator(s) are bullish while GOSS’s TA Score has 4 bullish TA indicator(s).

  • EBS’s TA Score: 4 bullish, 6 bearish.
  • GOSS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а +14.74% price change this week, while GOSS (@Biotechnology) price change was -13.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.10%. For the same industry, the average monthly price growth was +25.87%, and the average quarterly price growth was +18903.10%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.02%. For the same industry, the average monthly price growth was -8.35%, and the average quarterly price growth was +1260.86%.

Reported Earning Dates

EBS is expected to report earnings on Jul 25, 2024.

GOSS is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-2.10% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

@Biotechnology (-1.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for EBS with price predictions.
OPEN
A.I.dvisor published
a Summary for GOSS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
GOSS($160M) has a higher market cap than EBS($120M). EBS YTD gains are higher at: -9.167 vs. GOSS (-22.378).
EBSGOSSEBS / GOSS
Capitalization120M160M75%
EBITDA-518.2MN/A-
Gain YTD-9.167-22.37841%
P/E Ratio17.73N/A-
Revenue1.02BN/A-
Total Cash112MN/A-
Total Debt860MN/A-
FUNDAMENTALS RATINGS
EBS: Fundamental Ratings
EBS
OUTLOOK RATING
1..100
60
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
16
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EBSGOSS
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 3 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 25 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
EBSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GOSSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAOIX32.560.02
+0.06%
Fidelity Advisor Overseas I
SFSLX23.39N/A
N/A
1919 Financial Services C
VMIAX98.96N/A
N/A
Vanguard Materials Index Admiral
FLIAX9.32-0.01
-0.11%
First Sentier American Listed Infras Ins
BMCKX24.77-0.03
-0.12%
BlackRock Advantage Large Cap Gr K